The Lancet Oncology
Source
ISSNs 1470-2045, 1474-5488
Source type: journal
Publisher: Elsevier BV
Fully open access: No
In DOAJ: No
Article Processing Charge: $6,300
2yr mean citedness: 10.72
H-index: 481
I10-index: 4,108
Works count: 10,840
Citations count: 913,800
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
2009 · Roger Stupp, Monika E. Hegi, et al. · The Lancet Oncology
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
2008 · Ann‐Lii Cheng, Yoon‐Koo Kang, et al. · The Lancet Oncology
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
2012 · Rafael Rosell, Enric Carcereny, et al. · The Lancet Oncology